Cooperative Agreement UG3DA062088
Award Date
9/30/24
Completion Date
8/31/26
Dollars Obligated
$3.2M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
New York, NY 10016, USA
Similar Awards
This $495,024 Project Grant was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The project aims to examine the impact of psilocybin on brain mechanisms of motivation, inhibition, and cognitive flexibility in individuals with opioid use disorder. Specifically, the research will prospectively assess brain...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, provides $708,511 to conduct a mechanistic trial investigating the effects of psilocybin on neural activity, drinking outcomes, and self-report measures related to negative emotionality, craving, and executive function in individuals with alcohol use disorder. The study will randomly assign 90 participants currently in...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,837,542 to the University of Utah to investigate the safety, preliminary efficacy, and psycho-physiological mechanisms of Mindfulness-Oriented Recovery Enhancement (MORE) combined with ketamine for treating treatment-resistant opioid use disorder (OUD) in patients receiving buprenorphine. The project aims to first conduct a Phase 2...
This federal Project Grant award from the National Institute of Mental Health (NIMH), part of the Mental Health Research Grants program (CFDA 93.242), is funding a $627,945 research project at Cornell University to investigate the role of cortical GABAergic interneurons in the effects of the psychedelic drug psilocybin. The goal is to determine how the three major subtypes of inhibitory interneurons in the mouse medial frontal cortex respond to psilocybin administration, and whether modulating...
This Project Grant award from the National Center for Complementary and Integrative Health (NCCIH), under the Federal Grant Program "Research and Training in Complementary and Integrative Health" (CFDA 93.213), provides $236,250 to the University of California, Los Angeles (UCLA) to conduct a feasibility clinical trial of psilocybin-assisted cognitive behavioral therapy (PA-CBT) for the treatment of major depressive disorder. The study aims to refine and optimize the PA-CBT protocol...
This federal Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $679,118 to the University of California, Santa Cruz to investigate the cellular and circuit mechanisms underlying the long-lasting therapeutic effects of the psychedelic drug psilocybin in the stressed brain. The key objectives are to determine the acute and enduring effects of psilocybin on synaptic plasticity, cortical functional networks,...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $131,990.00 to the University of California, Irvine (UC Irvine) to examine the effects of psychedelic 5-HT2A agonist drugs on food-seeking behavior and reward circuit function in an established rat model of early-life adversity. The project aims to replicate and extend previous findings on the persistent reversal of aberrant...
The National Institutes of Health's National Institute on Drug Abuse awarded New York University School of Medicine a $1,446,310 Project Grant under the Drug Abuse and Addiction Research Programs to adapt an evidence-based posttraumatic stress disorder intervention for polysubstance use populations receiving treatment for opioid use disorder. Specifically, the award will support adapting an existing trauma-focused therapy, Skills Training in Affective and Interpersonal Regulation with...
The National Institute on Drug Abuse (NIDA) awarded a $683,583 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to New York University School of Medicine. The purpose of this 2-year grant, running from August 1, 2024 to July 31, 2026, is to use an agent-based computer simulation model to estimate the potential impacts of four alternative methadone treatment policy scenarios on methadone initiation, retention, opioid overdose, and disparities in New York State. The...
This $19,302,777 Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the CFDA 93.279 Drug Use and Addiction Research Programs, aims to accelerate the development of NRS-033, a new medication for the treatment of Opioid Use Disorder (OUD). The key activities funded through this award include late-stage chemistry, manufacturing, and controls (CMC) for the active pharmaceutical ingredient (API) and drug product, registration-enabling non-clinical studies, quality...